DK0788480T3 - Krystallisering af levobupivacain og analoger deraf - Google Patents

Krystallisering af levobupivacain og analoger deraf

Info

Publication number
DK0788480T3
DK0788480T3 DK95934738T DK95934738T DK0788480T3 DK 0788480 T3 DK0788480 T3 DK 0788480T3 DK 95934738 T DK95934738 T DK 95934738T DK 95934738 T DK95934738 T DK 95934738T DK 0788480 T3 DK0788480 T3 DK 0788480T3
Authority
DK
Denmark
Prior art keywords
pct
levobupivacaine
analogues
crystallization
sec
Prior art date
Application number
DK95934738T
Other languages
English (en)
Inventor
Marianne Langston
Benjamin Mark Skead
Original Assignee
Darwin Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9421476A external-priority patent/GB9421476D0/en
Priority claimed from GBGB9504926.8A external-priority patent/GB9504926D0/en
Application filed by Darwin Discovery Ltd filed Critical Darwin Discovery Ltd
Application granted granted Critical
Publication of DK0788480T3 publication Critical patent/DK0788480T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Epoxy Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK95934738T 1994-10-25 1995-10-23 Krystallisering af levobupivacain og analoger deraf DK0788480T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9421476A GB9421476D0 (en) 1994-10-25 1994-10-25 Process and salt
GBGB9504926.8A GB9504926D0 (en) 1995-03-10 1995-03-10 Crystallisation
PCT/GB1995/002513 WO1996012699A1 (en) 1994-10-25 1995-10-23 Crystallisation of levobupivacaine and analogues thereof

Publications (1)

Publication Number Publication Date
DK0788480T3 true DK0788480T3 (da) 2003-09-29

Family

ID=26305863

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95934738T DK0788480T3 (da) 1994-10-25 1995-10-23 Krystallisering af levobupivacain og analoger deraf

Country Status (16)

Country Link
US (1) US5994548A (da)
EP (1) EP0788480B1 (da)
JP (1) JP3911545B2 (da)
AT (1) ATE245629T1 (da)
AU (1) AU698637B2 (da)
CA (1) CA2200355C (da)
DE (1) DE69531356T2 (da)
DK (1) DK0788480T3 (da)
ES (1) ES2202375T3 (da)
FI (1) FI117438B (da)
HU (1) HU227420B1 (da)
MX (1) MX9703024A (da)
NO (1) NO309266B1 (da)
PL (1) PL183210B1 (da)
PT (1) PT788480E (da)
WO (1) WO1996012699A1 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0002246A (pt) * 2000-04-06 2003-04-15 Cristalia Prod Quimicos Farm Processo de obtenção dos enantiÈmeros da bupivacaìna racêmica, processo de obtenção de composições farmacêuticas a base de levobupivacaìna: composições farmacêuticas a base de levobupivacaìna formuladas nas formas básicas ou sais farmaceuticamente aceitáveis e utilização das composições farmacêuticas a base de levobupivacaìna formuladas nas formas básicas ou sais farmaceuticamente aceitáveis
BRPI0104491B8 (pt) * 2001-10-10 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda n-(2,6-dimetilfenil)-1-propil-2-piperidinocarboxamida; processo de obtenção dos enantiômeros; mistura não racêmica dos anantiômeros e seu processo de obtenção e composição farmacêutica.
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
ATE482695T1 (de) 2002-12-13 2010-10-15 Durect Corp Orale darreichungsform mit flüssigen hochviskosen trägersystemen
US7094812B2 (en) * 2003-04-24 2006-08-22 Xerox Corporations Colorant compositions
US6790267B1 (en) * 2003-04-24 2004-09-14 Xerox Corporation Colorant compositions
AU2005287175B2 (en) 2004-09-17 2011-12-01 Durect Corporation Sustained local anesthetic composition containing preferably a sugar ester such as SAIB
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
JP2009535327A (ja) * 2006-04-25 2009-10-01 ディシュマン・ファーマシューティカルズ・アンド・ケミカルズ・リミテッド ロピバカイン塩酸塩無水物およびその調製
US8337883B2 (en) 2006-11-03 2012-12-25 Durect Corporation Transdermal delivery systems
EP2219622A1 (en) 2007-12-06 2010-08-25 Durect Corporation Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
WO2009089841A1 (en) * 2008-01-15 2009-07-23 Pharmathen S.A. Process for the preparation of (s)-1-alkyl-2',6'-pipecoloxylidide compound
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
CN103073484B (zh) * 2013-01-28 2014-10-22 山东诚创医药技术开发有限公司 一种甲哌卡因及其光学对映体的制备方法
TW201521769A (zh) 2013-03-15 2015-06-16 Durect Corp 具有流變改質劑以減少溶解變異性之組成物
SG11201811760VA (en) 2016-07-06 2019-01-30 Durect Corp Oral dosage form with drug composition, barrier layer and drug layer
EP3558279A4 (en) * 2016-12-26 2020-12-02 Cellix Bio Private Limited COMPOSITIONS AND METHODS FOR THE TREATMENT OF CHRONIC PAIN
CN115666621A (zh) 2020-01-13 2023-01-31 度勒科特公司 具有减少的杂质的持续释放药物递送系统及相关方法
CA3203561A1 (en) 2021-01-12 2022-07-21 Adrian Neil Verity Sustained release drug delivery systems and related methods

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE341404B (da) * 1967-05-18 1971-12-27 Sterling Drug Inc
US4695576A (en) * 1984-07-09 1987-09-22 Astra Lake Medel Aktiebolag L-N-n-propylpipecolic acid-2,6-xylidide

Also Published As

Publication number Publication date
AU698637B2 (en) 1998-11-05
AU3704895A (en) 1996-05-15
PT788480E (pt) 2003-12-31
CA2200355A1 (en) 1996-05-02
FI971711A0 (fi) 1997-04-22
DE69531356D1 (de) 2003-08-28
JPH10507464A (ja) 1998-07-21
DE69531356T2 (de) 2004-05-27
PL319829A1 (en) 1997-09-01
CA2200355C (en) 2007-03-06
ES2202375T3 (es) 2004-04-01
NO971903D0 (no) 1997-04-24
MX9703024A (es) 1997-10-31
NO309266B1 (no) 2001-01-08
US5994548A (en) 1999-11-30
HU227420B1 (en) 2011-05-30
NO971903L (no) 1997-04-24
FI117438B (fi) 2006-10-13
JP3911545B2 (ja) 2007-05-09
PL183210B1 (pl) 2002-06-28
FI971711L (fi) 1997-04-22
HUT77631A (hu) 1998-06-29
EP0788480B1 (en) 2003-07-23
ATE245629T1 (de) 2003-08-15
EP0788480A1 (en) 1997-08-13
WO1996012699A1 (en) 1996-05-02

Similar Documents

Publication Publication Date Title
DK0788480T3 (da) Krystallisering af levobupivacain og analoger deraf
ATE148130T1 (de) Typ-iv-dipeptidyl-aminopeptidase-inhibitoren
DE69406522D1 (de) Verfahren zur Herstellung von alkalilöslichen Emulsionscopolymeren
DE69200983D1 (de) Verfahren zur Herstellung von Wasserstoffsuperoxyd.
DE69101775D1 (de) Verfahren zur Herstellung von Wasserstoffperoxid.
ATE248148T1 (de) Verfahren zur herstellung von levobupivacaine und analoge
DE69109401D1 (de) Wässrige Zusammensetzungen zur Behandlung von porösen Substraten.
DK0476113T3 (da) Lægemiddel til behandling af hyperlipidæmi og/eller atherosklerose
NO20013128D0 (no) Sementblanding og fremgangsmåte dertil
DE59106800D1 (de) Verfahren zur Herstellung von Benzylketonen.
DE59204902D1 (de) Verfahren zur Herstellung von Diphenylaminen
DK0821588T3 (da) Levobupivacain og anvendelse heraf som et anæstetikum til gravide kvinder
DK0687256T3 (da) Hydroxymethylfurazancarboxylsyrederivater og deresanvendelse ved behandling af kardiovaskulære sygdomme
DE59407675D1 (de) Verfahren zur Herstellung von 6H-Dibenz-(c,e)(1,2)-oxaphosphorin-6-on
DK0586589T3 (da) Amylin- eller amylinanalogpræparat, som eventuelt indeholder insulin, til behandling af anoreksi og beslægtede tilstande
DK0620607T3 (da) Fremgangsmåde til elektrolytisk behandling af brugte batterier
ES2116089T3 (es) Elemento de bastidor.
ES2162078T3 (es) Compuestos terapeuticos.
DE58902228D1 (de) Verfahren zur herstellung von 5-gliedrigen, stickstoffhaltigen heteroaromaten.
DE69103913D1 (de) Verfahren zur Herstellung von Dodekandicarbonsäure.
NO881414D0 (no) Fremgangsmaate for behandling av spillvann og annet urent vann.
ATE131936T1 (de) Vorrichtung zur befestigung von zwei oder mehreren seismischen energiequellen an relativ fixierte positionen
ATE84780T1 (de) Neue di(meth)acrylate, verfahren zu deren herstellung und deren verwendung.
DE59200254D1 (de) Verfahren zur Herstellung von N-(Hydroxyalkyl)-carbamidsäure- alkylestern.
DE59106854D1 (de) Verfahren zur Herstellung von N-(2-Chlor-pyridin-5-yl-methyl)-ethylendiamin.